MediWound opened lower at $12.60, compared with its previous close of $13.82. In the last trading session, the stock traded between $12.46 and $13.53. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in MediWound is now worth
$ 58.66
Resulting in a loss of
$ 41.34 (41.34%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.72 (-5.22%)
Day High
$13.53
Day Low
$12.46
Day Open
$12.60
Prev Close
$13.82
Volume
2,60,170
1W Return
-7.61%
1M Return
4.17%
3M Return
-6.04%
6M Return
-20.43%
1Y Return
-29.28%
Fundamentals
Market Cap ($ Mn)
169
PE Ratio
-
PB Ratio
4.59
PEG Ratio
-
ROE
-67.71%
ROCE
-48.30%
EPS (TTM)
$-0.57
Investment Returns
1 Week
-7.61%
1 Month
4.17%
3 Months
-6.04%
6 Months
-20.43%
9 Months
-24.07%
Financials
Quarterly
All values in $ Mn
4.0
Mar 25
5.7
Jun 25
5.4
Sep 25
1.9
Dec 25
1.5
Mar 26
3.1
Jun 26
Updates
4Nov
MediWound announces $15 million share offering at $12.50 per share
MediWound announced a $15 million bought deal offering of 1.2 million shares. Shares are priced at $12.50 each with expected closing on November 5, 2026. H.C. Wainwright & Co. serves as sole book-running manager for the offering. Underwriter holds a 30-day option to purchase an additional 180,000 shares.
9 days ago
13Aug
MediWound Q2 sales beat estimates; EPS miss widens as R&D rises
MediWound reported Q2 2026 revenue of $3.1 million, beating estimates but falling 45.8% YoY due to BARDA funding timing. EPS loss widened to $(0.77), missing forecasts, as R&D expenses surged to $5.9 million for the EscharEx Phase 3 trial. Management reaffirmed full-year 2026 revenue guidance of $24-26 million, citing H2 strength from government contracts and a new Vericel MSA. Cash reserves stood at $36 million.
